

Supplier tax

Guidelines 2024

01/01/2024

		•	•	•			•							•							•	•		•	•	•
						•	•					•	•		•							•	•		•	
•			•		•	•	•		•		•	•				•	•			•			•		•	
•	•	•	•	•		•	•		•		•	•	•	•	•	•	•	•		•	•	•	•	•	•	
•	•	•	•				•			•		•	•		•	•	•	•		•			•	•		
•	•		•		•	•		•	•		•		•		•		•	•	•		•		•	•		•
•			•	•	•	•	•	•		•			•	•	•	•	•	•		•	•	•		•	•	•
	•		•	•	•	•	•	•	•	•	•	•	•		•	•	•	•	•	•	•	•	•	•		•
•	•	•	•	•	•	•	•	•		•	•	•	•	•	•	•	•		•	•	•	•			•	•
•	•	•	•	•	•	•	•	•		•	•	•	•	•		•	•	•	•	•	•	•	•	•		•
•	•	•	•	•		•	•	•	•	•	•	•	•	•	•	•	•	•	•		•	•	•	•	•	•
•		•	•	•	•	•	•	•	•	•		•			•	•	•	•	•	•	•	•	•	•	•	•
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•		•	•	•	•
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•
•	•	•	•	•	•	•	•	•	•	•		•	•	•	•	•	•	•	•	•	•	•	•	•	•	•
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•
•	•	•	•	•	٠	•	•	•	•	•	•	•	•	•	•	•	•	•	٠	•	•	•	•	•	•	•
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	٠	•	•	•	•	•	٠	•	•
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•
•	•	•	٠	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	٠	•	•
•	•	•	•	•	•	•	•	•	٠	•	•	•	•	•	•	•	•	•	٠	•	•	•	•	•	•	•

Table of contents

Purpose	3
Legal framework	3
Actors liable for payment	3
Tax basis and rate	3
Reporting	4
Deadlines	4
Invoicing and payment	4
Auditor's signature	5
Failure to report/	5
payment	5
Contact information	

Purpose	The supplier tax shall cover the authorities' expenses for quality control, monitoring of side effects, information on drugs, regulatory and scientific guidance, health technology assessments, supervision of drug advertising and pricing of drugs. The tax shall also cover the authorities' expenses for participation in scientific committees and permanent working groups in the EU/EEA cooperation, quality assurance and the issuing of documents related to marketing authorizations and marketing in Norway that are not covered by fees or assignment income.
Legal framework	Legal reference The tax is authorized in legemiddelforskriften § 15-3, cf. legemiddelloven § 10.
Actors liable for	Marketing authorization holder (MAH) in Norway.
payment	In the case of an authorized representative on behalf of the MAH, it must be clearly stated which tasks the authorized representative undertakes.
	The authorized representative must, in an attachment to the reporting form, specify which companies they represent, and which turnover and fee is being reported/paid on their behalf.
	MAH is financially and legally responsible for correct reporting.
Tax basis and rate	Rate
	The tax rate for 2024 is 1,00 % of taxable turnover.
	 The tax rate for 2024 is 1,00 % of taxable turnover. Tax basis Turnover from sales of drugs with market authorization in Norway. The wholesaler's real purchase price, minus VAT and discounts.
	Tax basis - Turnover from sales of drugs with market authorization in Norway.

Reporting	 Reporting form The form is available at www.noma.no. Electronic completion in the Excel form is recommended, due to automatic formulas.
	Completion and submission
	 Form: Complete all fields, except fields with formulas; use net amount without VAT and discounts; round amounts to whole kroner; correct invoice address and reference number; do not remove formulas from the form.
	 Submission: Periodic submission. Small amounts can be sent annually, by agreement. To be sent by e-mail to leverandoravgift@dmp.no.
	3) Correction: In the event of an error, please send a corrected form.
	NB! All taxable turnover must be reported, including zero value.

Deadlines

Reporting

The deadline for reporting is no later than one month after the end of the quarter:

Quarter	Period	Deadline
Q1	January-March	May 1 st
Q2	April-June	August 1 st
Q3	July-September	November 1 st
Q4	October-December	February 1 st

Payment deadline

- 30 days from the invoice date.
- In case of late reporting, the payment deadline can be reduced to 14 days.

Annual financial statements and auditor's confirmation

- Is sent to the Norwegian Medical Products Agency (NoMA) no later than two months into the following calendar year.
- In the event of cessation of business, auditor-certified reporting and settlements must be made within the following tax term.

Invoicing and

Invoicing

payment

- NoMA issues the invoice.

- The fee is rounded to the nearest kroner.

Payment

Payment label: customer and invoice number, if OCR/KID is not used.

Auditor's signature	After the reporting form has been completed, an auditor's attestation for the applicable calendar year is required. The document must be sent to NoMA no later than two months into the following calendar year. The attestation means that the auditor gives their signature as confirmation of the following points:
	 a) that the tax amount stated corresponds to the company's registration of taxable pharmaceutical sales. The auditor hereby verifies that the booked amounts are correct. b) that the business has established a reliable system for ongoing registration of taxable turnover and calculation of the tax. The auditor must also confirm, on the basis of random checks, that this system works as intended.
	For the auditor's signature to be valid, the auditor must either sign the reporting form itself or an addendum to the reporting form, where the above-mentioned points a) and b) are confirmed.
	Exception In the case of low turnover, the NoMA can, based on a discretionary assessment and upon application from the company liable to tax, grant exemptions from the auditor's signature for the tax year in question.
	To be sent by e-mail to leverandoravgift@dmp.no.
Failure to report/ payment	In the event of non-reporting/payment, the NoMA can determine the fee at its discretion, cf. §28, fifth subsection of legemiddelloven.

Contact information

Questions/ Inquiries	Point of contact:	E-mail:				
Faktura og betaling:	Accounting	Regnskap@dmp.no				
Regulations and other inquiries:	Distribution chain economics	Leverandoravgift@dmp.no				